|1.||Cavalli, Laura: 1 article (04/2013)|
|2.||Di Ianni, Mauro: 1 article (04/2013)|
|3.||Del Papa, Beatrice: 1 article (04/2013)|
|4.||Bartoli, Andrea: 1 article (04/2013)|
|5.||Sabatini, Rita: 1 article (04/2013)|
|6.||Screpanti, Isabella: 1 article (04/2013)|
|7.||Fettucciari, Katia: 1 article (04/2013)|
|8.||Falzetti, Franca: 1 article (04/2013)|
|9.||De Falco, Filomena: 1 article (04/2013)|
|10.||Marconi, Pierfrancesco: 1 article (04/2013)|
|1.||Melanoma (Melanoma, Malignant)
|2.||Breast Neoplasms (Breast Cancer)
01/01/2009 - "Furthermore, we observed that Z-LLNle-CHO could inhibit proteasome activity and the relative cellular sensitivity of these six breast cancer cell lines to Z-LLNle-CHO was the same as observed for three proteasome inhibitors. "
01/01/2009 - "Consistent with this hypothesis, two recent papers reported that gamma-secretase inhibitor I (GSI I), Z-LLNle-CHO, is toxic to breast cancer cells both in vitro and in vivo. "
01/01/2009 - "We conclude that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition."
01/01/2009 - "We found that blocking gamma-secretase activity by DAPT and L-685,458 had no effect on the survival and proliferation of a panel of six breast cancer cell lines while Z-LLNle-CHO could cause cell death even at concentrations that inhibited gamma-secretase activity less efficiently. "
01/01/2009 - "In this study, we compared the activity and cytotoxicity of Z-LLNle-CHO to that of two highly specific GSIs, DAPT and L-685,458 and three structurally unrelated proteasome inhibitors, MG132, lactacystin, and bortezomib in order to study the mechanism underlying the cytotoxicity of Z-LLNle-CHO in breast cancer cells. "
|3.||Alzheimer Disease (Alzheimer's Disease)
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/01/2011 - "As GSI-I (Z-LLNle-CHO) is also a derivative of a widely used proteosome inhibitor MG-132, we hypothesized that this compound might be active in precursor-B acute lymphoblastic leukemia (ALL) cell lines and patient samples. "
07/01/2011 - "GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia."
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
07/01/2011 - "Using Z-LLNle-CHO in a nonobese diabetes/severe combined immunodeficiency (NOD/SCID) precursor-B ALL xenograft model, we found that GSI-I alone delayed or prevented engraftment of B-lymphoblasts in 50% of the animals comprising the experimental group, suggesting that this compound is worthy of additional testing."
|1.||Amyloid Precursor Protein Secretases (beta-Secretase)
|2.||Proteasome Endopeptidase Complex (Proteasome)
|7.||2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
|1.||Heterologous Transplantation (Xenotransplantation)